

**FEMOROPOPLITEAL DISEASE
INCIDENCE OF RESTENOSIS
AFTER ENDOVASCULAR REVASCULARIZATION
AND REVIEW OF COST-EFFECTIVENESS ANALYSES**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2020

All rights reserved, including the right of reproduction
in whole or in part in any form.

INDEX OF TABLES

Table 1: Target Lesion Revascularization Rates by Device Type in Clinical Trials and Registries	7.
Table 2: Long Term Target Lesion Revascularization Rates	7.
Table 3: Percutaneous Transluminal Angioplasty Target Lesion Revascularization Rates in Clinical Trials and Registries	13.
Table 4: Heterogeneity of Selected Patient and Lesion Characteristics in Percutaneous Transluminal Angioplasty Clinical Trials and Registries	14.
Table 5: Percutaneous Transluminal Angioplasty Pooled Target Lesion Revascularization Rates	15.
Table 6: Bare Metal Stent Target Lesion Revascularization Rates in Clinical Trials and Registries	16.
Table 7: Heterogeneity of Selected Patient and Lesion Characteristics in Bare Metal Stent Clinical Trials and Registries	18.
Table 8: Bare Metal Stent Pooled Target Lesion Revascularization Rates	19.
Table 9: Drug-Eluting Stent Target Lesion Revascularization Rates in Clinical Trials and Registries	20.
Table 10: Heterogeneity of Selected Patient and Lesion Characteristics in Drug-Eluting Stent Clinical Trials and Registries	20.
Table 11: Drug-Eluting Stents Pooled Target Lesion Revascularization Rates	21.
Table 12: Drug-Coated Balloon Target Lesion Revascularization Rates in Clinical Trials and Registries	22.
Table 13: Heterogeneity of Selected Patient and Lesion Characteristics in Drug-Coated Balloon Clinical Trials and Registries	23.
Table 14: Drug-Coated Balloon Pooled Target Lesion Revascularization Rates	24.
Table 15: Atherectomy and Percutaneous Transluminal Angioplasty Target Lesion Revascularization Rates in Clinical Trials and Registries	25.
Table 16: Long Term Target Lesion Revascularization Rates in Clinical Trials and Registries	26.
Table 17: Long Lesions Target Lesion Revascularization and Primary Patency Rates	28.
Table 18: Heterogeneity of Selected Patient and Lesion Characteristics in Long Femoropopliteal Disease Trials and Registries	29.
Table 19: Critical Limb Ischemia Patients Treated for Femoropopliteal Disease Target Lesion Revascularization and Primary Patency Rates	33.

Table 20: Comparison of Multiple Device and Single Device 12-Month TLR Rates in Femoropopliteal Disease Treatment	34.
Table 21: 24-Month Average Cost per Patient of Index Intervention, Reintervention and Target Lesion Revascularization Rates by Device Type in Treatment of Femoropopliteal Disease	38.
Table 22: Number Needed to Treat to Avoid One TLR DCB and DES Compared with Other Treatment Strategies	39.
Table 23: Actual U.S. Cost of Femoropopliteal Disease Treatment with Admiral DCB and Percutaneous Transluminal Angioplasty	41.
Table 24: 2016 Endovascular Reimbursement by Device Type for Treatment of Femoropopliteal Disease	43.
Table 25: Two-Year Reintervention Rate by Type of Device Employed in Index Procedure	44.
Table 26: United States Two-Year Cost-Effectiveness Analysis by Device Type	45.
Table 27: UK 24-Month Average Cost per Patient of Index Intervention, Reintervention and TLR Rates by Device Type	47.
Table 28: Germany 24-Month Average Cost per Patient of Index Intervention and Reintervention and TLR Rates by Device Type	50.
Table 29: German CONSEQUENT Trial 24-Month Average Cost per Patient of Index Intervention and Reintervention and TLR Rates by Device Type	50.

CONTACT INFORMATION

Mary L. Yost
President
Telephone (404) 520-6652
yost@thesagegroup.us